Theraclion has disclosed the total number of voting rights and shares comprising its share capital as of June 30, 2026. The filing provides details on the theoretical and actual voting rights attached to the company's shares.

Share Capital and Voting Rights

The company reported a total of 73,123,311 shares. The total number of theoretical voting rights stood at 89,137,355, while the total number of real voting rights was 87,570,061.

Regulatory Definitions

Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation. Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.

Theraclion is developing Sonovein®, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein® is not yet available for sale. Based in Malakoff (Paris), the Theraclion team consists of approximately 35 people.

Theraclion has appointed Claude Lenoir as Interim Chairman of the Board of Directors with immediate effect, following the decision by Yann Duchesne not to stand for re-election as Director and Chairman. The change in leadership was approved by shareholders during the General Meeting held on June 18, 2026. Duchesne had held these positions since January 24, 2022.

The new Board of Directors appointed by shareholders includes Ms. Lijuan Deng, Mr. Claude Lenoir, Mr. Cédric Bellanger, Mr. Mehdi El Glaoui and Mr. Vincent Gardès. Vincent Gardès joins the Board after serving as an observer in recent months. The appointment of Lenoir as Interim Chairman ensures continuity of governance pending the appointment of a permanent Chairman.

Board Composition

Martin Deterre, Chief Executive Officer of Theraclion, thanked Duchesne for his contributions to the company's strategic direction and international expansion. Deterre also expressed confidence in Lenoir's ability to lead the governance evolution.

About Theraclion

Theraclion is a MedTech company developing Sonovein, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU). The technology is CE-marked under MDR (EU 2017/745) and has been used in over 4,000 procedures across more than a dozen centres worldwide. The company is listed on Euronext Growth Paris under the ticker ALTHE.